Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Malignant Neoplasm
75%
Ligase
50%
Neoplasm
25%
Adverse Drug Reaction
25%
Metastasis
25%
Antiapoptotic
25%
Antiinfective Agent
25%
Leukemia
25%
Anticarcinogen
25%
Cancer Recurrence
25%
Mouse Model
25%
Acute Myeloid Leukemia
25%
Venetoclax
25%
Drug Selectivity
25%
Clinical Trial
25%
Antitumor Activity
25%
Chemotherapy
25%
Keyphrases
Targeted Degradation
83%
Bcl-xL
66%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
33%
Bcl-xL Inhibitor
31%
Senescent Cells
25%
Platelets
25%
E3 Ligase
16%
Leukemia Patients
16%
Drug Resistance
8%
In Vivo Assay
8%
Long-term Adverse Effects
8%
Bcl-2 Family Proteins
8%
Clinical Trials
8%
Senolytics
8%
In Vivo Efficacy
8%
Targeted Therapy
8%
Cancer Relapse
8%
Efficacy Data
8%
Tumor Xenograft
8%
Venetoclax
8%
B-cell Lymphoma 2 (Bcl-2)
8%
Antitumor Activity
8%
Drug-like
8%
Cancer Targeting
8%
Cancer Metastasis
8%
Preclinical Efficacy
8%
FDA-approved Drugs
8%
Anticancer Agents
8%
Small Molecules
8%
Leukemia
8%
Mouse Xenograft Model
8%
Acute Myeloid Leukemia
8%
Selective Inhibitor
8%
Chemotherapy-induced
8%
Proteolysis Targeting chimera (PROTAC)
8%
Anti-apoptotic Bcl-2
8%
Drug Relapse
8%
Therapeutic Strategies
8%
Patient-derived Xenograft
8%
Mouse Model
8%